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New drugs have signiﬁcantly improved the survival of patients with multiple myeloma (MM), but the
prognosis of MM patients with high-risk cytogenetic changes such as t(4; 14), t(14; 16) or del17p remains
very poor. A natural product, komaroviquinone (KQN), was originally isolated from the perennial semi-
shrub Dracocephalum komarovi and has anti-protozoal activity against Trypanosoma cruzi, the organism
causing Chagas’ disease. Here we demonstrate that a novel KQN-derivative, GTN024, has an anti-MM
effect both in vitro and in vivo. GTN024 induced the apoptosis of MM cell lines including those with
high-risk cytogenetic changes. GTN024 produced reactive oxygen species (ROS) and increased phos-
phorylated eIF2a. The ROS production and subsequent endoplasmic reticulum (ER) stress are thought to
play a key role in GTN024-induced apoptosis, as the apoptosis was completely abrogated by anti-oxidant
treatment. In a mouse xenograft model, an intraperitoneal injection of 20mg/kg of GTN024 signiﬁcantly
delayed tumor growth. Hematological toxicity and systemic toxicity as indicated by weight loss were not
observed. These results suggest that the novel KQN-derivative GTN024 could become a candidate drug
for treating high-risk MM.
© 2018 Elsevier Inc. All rights reserved.1. Introduction
Multiple myeloma (MM) is a B-cell neoplasm that causes clonal
plasma cell proliferation in bone marrow and bone lesions. The 5-
year prevalence rate of MM incidence in Japan is reported to be
9.7 per 100,000 persons [1]. New agents such as proteasome in-
hibitors and immunomodulatory drugs (IMiDs) have signiﬁcantly
improved the overall survival of MM patients [2e5], drugs from
different categories such as a histone-deacetylase inhibitor [6], an
anti-SLAMF7 antibody [7], and an anti-CD38 antibody [8] have alsoherapeutics, Keio University
ri).been reported to be effective for refractory MM in combination
therapy with IMiDs and proteasome inhibitors.
Despite these advances, the survival of certain groups of MM
patients remains unsatisfactory [9e11]. Those patients are known
as having ‘high-risk MM,’ and their MM cells frequently possess
chromosomal abnormalities such as t(4; 14), t(14; 16), del17p, and
1q21 ampliﬁcation. The revised International Staging System in-
dicates that the overall survival of the patients with high-risk
cytogenic abnormalities is signiﬁcantly short [12]. Another limita-
tion of newly developed drugs is their toxicities [13,14], which
impede the optimal drug efﬁcacy and result in unsatisfactory
treatment outcomes, especially among elderly patients. New ther-
apeutic modalities that are effective for high-risk MMwith less side
effects are thus currently an unmet clinical need in MM treatment.
A series of anti-neoplastic drugs were developed from natural
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activities of anti-protozoal agents. For example, nifurtimox, a
drug for Chagas’ disease, showed anti-tumor effects against neural
tumor cells. Nifurtimox induced the apoptosis of neuroblastomas
by inhibiting extracellular signal-regulated kinase (ERK) phos-
phorylation [15]. Artesunate, an anti-malaria drug, also showed
anti-MM effects by inhibiting nuclear factor-kappa B (NFkB) func-
tion [16]. With these drugs, the anti-tumor activities were discov-
ered as off-target effects in drug repositioning studies.
Komaroviquinone (KQN) is one of the natural products isolated
from the perennial semi-shrub Dracocephalum komarovi (family
Laminaceae), which shows anti-protozoal activities. Suto et al. re-
ported the asymmetric synthesis of KQN [17]. In a study of the
structure activity relationship study of KQN [17], a series of low-
molecular-weight compounds were discovered to exhibit prom-
ising anti-protozoal activities against Trypanosoma cruzi, which is
the causative pathogen of Chagas’ disease [18]. It is also reported
that KQN was reduced by T. cruzi old yellow enzyme (TcOYE) to
form its semiquinone and produced reactive oxygen species (ROS),
which showed trypanocidal activities [19]. A biomedical assay of
both KQN and its derivatives demonstrated that the new KQN-
derivative GTN024 had high anti-proliferation activities against
MM cells [20]. In addition, in the above-cited structure-activity
relationship study, GTN024 was shown to be readily accessible and
a valuable compound for the further pharmacodynamic study of
MM cells [20].
With this background, we carried out the present study to
determine the anti-tumor effects of GTN024 on MM cell lines
including those with high-risk cytogenetic changes, and we clari-
ﬁed this promising new drug's mode of action and safety.
2. Materials and methods
2.1. Cells
The human myeloma cell lines KMM1, KMS11, KMS21, KMS26,
KMS27, KMS28 and KMS34 were kindly provided by Dr. T. Otsuki
(Kawasaki Medical School, Kurashiki, Japan) [21]. The cell line
MUM24 was established in our laboratory from a patient with
thalidomide-resistant MM [22]. These cell lines were maintained in
RPMI1640 medium (Sigma-Aldrich, St. Louis, MO, USA) containing
10% fetal bovine serum (FBS, Gibco, Life Technologies, Carlsbad, CA)
and 1% penicillin-streptomycin (Pen Strep, Gibco). Chronosomal
abnormalities were detected by the ﬂuorescence in situ hybridiza-
tion (FISH) analysis. (LSI medience, Tokyo).
2.2. Reagents
GTN024 (Fig. 1A) was prepared as described by Suto et al. [18]. In
the present in vitro study, GTN024 was diluted in phosphate-
buffered saline (PBS, Sigma-Aldrich) containing 1% Tween®80
(Otsuka Pharmaceutical, Tokyo) and 10% DMSO.
2.3. Patient's samples
Bone marrow samples were collected fromMM patients treated
at Tokyo Saiseikai Central Hospital. The collection of clinical sam-
ples was approved by ethical committee of Saiseikai Central Hos-
pital (No. 28e66) and the Faculty of Pharmacy, Keio University (No.
170616e5, 180615e5). Written informed consent for their samples
to be used was obtained from all patients. Cells were isolated by
centrifugation with Lymphoprep™ (Axis-Shield, Oslo, Norway).
Cells were labeled with CD138 MicroBeads (Miltenyi Biotec, Ber-
gisch Gladbach, Germany). The magnetically labeled CD138-
positive cells were puriﬁed by MACS Columns (Miltenyi Biotec).2.4. Trypan blue exclusion assay
Cells (2 105 cells/mL) were seeded on six-well plates and
cultured in various concentrations of GTN024 (0e20 mM) with or
without 6mMofN-acetyl cysteine (NAC, Sigma-Aldrich) or 3mMof
glutathione (GSH, Sigma-Aldrich) at 37 C in 5% CO2. The cells were
stained with Trypan Blue Stain 0.4% (Gibco) and viable cells were
counted by an automatic cell counter TC20™ (Bio-Rad, Hercules,
CA). Viable cells were counted three times, and the average was
calculated. The IC50 of GTN024 was calculated by approximation.
2.5. MTT assay
Collected clinical samples (6 104 cells/mL) were seeded on 96-
well plates and cultured with various concentrations of GTN024
(0e30 mM) at 37 C in 5% CO2 for 48 h. The viability of the cells was
calculated byMTT dye absorbance (Roche Diagnostics, Indianapolis,
IN) according to the manufacturer's instructions.
2.6. Apoptosis detection assay
Cells (2 105 cells/mL) were seeded on six-well plates and
cultured at 37 C in 10 mM GTN024 for 72 h. Apoptotic cells were
detected by an annexin V-FITC Apoptosis Detection Kit (BioVision,
San Francisco, CA) following the manufacturer's protocol. Brieﬂy,
cells were collected and resuspended in 500 mL of 1 Binding
Buffer and stained with annexin V eFITC and propidium iodide (PI)
for 5min. The cells were analyzed using a BD™ LSRⅡ ﬂow cytom-
eter (Becton Dickinson, Lincoln Park, NJ).
2.7. Detection of reactive oxygen species
Cells (2 105 cells/mL) were seeded on six-well plates and
cultured at 37 C with or without 6mM NAC or 3mM GSH for 2 h.
Then, 20 mM GTN024 was added and incubated in 5% CO2. After
72 h, 1 mM chloromethyl-dichlorodihydroﬂuorescein diacetate,
acetyl ester (CM-H2DCFDA, Invitrogen, Carlsbad, CA) was added
and incubated for 30min. The stained cells were analyzed using the
BD LSRⅡ ﬂow cytometer.
2.8. Western blotting
Cells were cultured with GTN024 and lysed in 1% NP-40 buffer
containing 1mM PMSF, 1mM Na2PO4, 20mM NaF, 2mM Na2PO7,
and protease inhibitors (Complete Protease Inhibitor Mixture,
Roche Diagnostics, Mannheim, Germany). After incubation for
10min on ice, the lysates were centrifuged at 15,000 rpm for
10min at 4 C, and the supernatants were collected. The amount of
protein was evaluated by BCA Protein Assay Kit (Thermo Fisher
Scientiﬁc, Waltham, MA).
The lysates were mixed with Laemmli's buffer (1.33% SDS, 10%
glycerol, 0.083M Tris-HCl, 0.04% bromphenol blue, 2% 2-ME) and
boiled for 5min. The lysates were subjected onto 10% sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE),
and transferred to a PVDF membrane. The membranes were
blocked with 5% skim milk and then immunoblotted. Antibodies
against eIF2a (Cell Signaling Technology, Danvers, MA), p-eIF2a
(Cell Signaling Technology), b-actin (Santa Cruz Biotechnology,
Santa Cruz, CA), and cleaved caspase-3 (Cell Signaling Technology)
(diluted at 1:1000) was used. The second antigen-antibodies was a
horseradish peroxidase (HRP)-coupled anti-rabbit, anti-mouse Ig
antibody (diluted at 1:500). Antigen-antibody complexes were
detected using enhanced chemiluminescence (Amersham, Arling-
ton Heights, IL).
Fig. 1. GTN024 induced cell death in MM cell lines and MM patients. (A) The chemical structures of komaroviquinone and GTN024. (B) The inhibitory effects of GTN024 on MM
cells with chromosomal abnormalities [22,35]. Cells were cultured with GTN024 for 48 h. The number of viable cells was counted by staining with trypan blue. Bars: means ± SD,
n ¼ 3. *p < 0.05 vs. control. (C) The inhibitory effects of GTN024 on MM clinical samples. Cells were collected from clinical bone marrow samples obtained from three MM patients.
The viability of CD138þ cells treated with GTN024 was measured by MTT assay. Bars: indicate means ± SD, n ¼ 3. *p < 0.05 vs. control. (For interpretation of the references to color in
this ﬁgure legend, the reader is referred to the Web version of this article.)
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To evaluate the toxicity of GTN024 in vivo, we intraperitoneally
injected 0, 10, 20, or 40mg/kg of GTN024 in 1% Tween®80 and 10%
DMSO in saline to 5-wk-old male ICR mice (Clea, Tokyo) daily for
three consecutive days. The body weights of the mice were
measured every 3 days. We took peripheral blood samples with a
heparinized hematocrit tube (Terumo, Tokyo) from the tail veins of
the mice every 3 days. Blood samples were diluted 10 times by
Türk's solution (Merck, Darmstadt, Germany), and the numbers of
leukocytes and neutrophils were counted under a light microscope.
All animal experiments were approved by the Ethics Committee for
Animal Experiments at Keio University (Approval no. 12067-(2)).
2.10. In vivo tumor growth assay
KMS11 cells (3 107 cells) were inoculated into 5-wk-old male
ICR/SCID mice (Clea) subcutaneously in the ﬂank. When the
resulting tumors reached 100mm3, 20mg/kg of GTN024 (1%
Tween®80,10% DMSO in saline) was injected intraperitoneally daily
for three consecutive days. The tumor volume was calculated by
lengthwidth2 0.52 [23].
2.11. Histopathologic examination
Xenografted mice were sacriﬁced, and isolated tumors were
ﬁxed with 10% formalin and embedded in 5-mm pieces of parafﬁn.
Sliced sections were stained with hematoxylin and eosin (H&E).
Anti-human cleaved PARP polyclonal antibody (Cell Signaling
Technology Japan, Tokyo), anti-human cleaved caspase-3 (Asp175)
polyclonal antibody (Cell Signaling Technology Japan), anti-human
Ki-67 monoclonal antibody (clone MIB-1) (Dako Japan, Tokyo), and
anti-human PCNA polyclonal antibody (Atlas Antibodies,Stockholm, Sweden) were used for immunohistochemistry.
2.12. Statistical analysis
The signiﬁcance of differences was determined using Student's
t-test. The level of signiﬁcance was set at p< 0.05.
3. Results
3.1. GTN024 inhibited the growth of MM cells
We examined the tumoricidal effects of GTN024 against various
MM cell lines. GTN024 induced the cell death of all of the MM cell
lines tested (KMM1, KMS11, KMS21, KMS26, KMS27, KMS28,
KMS34, andMUM24) (Fig. 1B). IC50 varied from 3.36 mM (KMS21) to
16.5 mM (KMS28). One arm of chromosome 17 is deleted in KMM1,
KMS11, KMS26, KMS34 and MUM24 cells, and KMS11, KMS26,
KMS28, KMS34 and MUM24 also show t(4; 14) (our unpublished
data).
We then examined whether GTN024 could induce cell death in
CD138þ cells obtained from three MM patients. Patient #1 and #2
had untreated MM and both of their MM cells had 1q21 ampliﬁ-
cation. Patient #3 had been treated with and showed resistance to
bortezomib, lenalidomide, pomalidomide, ixazomib, and elotuzu-
mab. Based on the results shown in Fig. 1C, their IC50 values in
response to GTN024 were calculated as 5.09 mM (patient #1),
5.94 mM (patient #2), and 0.84 mM (patient #3).
3.2. Anti-MM effect via the ROS production of GTN024
We examined the ROS production in GTN024-treated MM cells.
The ﬂow cytometric analysis using CM-H2DCFDA showed that
GTN024 signiﬁcantly induced ROS production in MM cells (Fig. 2A).
Fig. 2. GTN024 treatment resulted in ROS-mediated apoptotic cell death. (A) MUM24 cells (2 105 cells/mL) were incubated with or without NAC or GSH for 2 h and GTN024 was
added. ROS levels were determined by staining with CM-H2DCFDA. Stained cells were analyzed using a FACS BD LSRⅡ. (B) MUM24 cells (2 105 cells/mL) were cultured with NAC or
GSH for 2 h, and GTN024 was added. The number of viable cells was counted by staining with trypan blue. Bars: mean ± SD, n ¼ 3. *p < 0.05 vs. control. (C) MUM24 cells
(2  105 cells/mL) were cultured with 10 mM GTN024 for 72 h stained with Annexin V-FITC and propidium iodide (PI) followed by an analysis with the BD LSRⅡ system.
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depends on ROS production. As shown in Fig. 2B, the growth in-
hibition by GTN024 treatment was mostly abrogated when the MM
cells were preincubated with anti-oxidants. The ﬂow cytometric
analysis also showed that the GTN024 treatment of MM cells
increased the number of annexin Vþ cells, indicating that GTN024
induced apoptosis (Fig. 2C).3.3. Excessive ER stress pathway appears to be the cause of
GTN024's anti-MM activity
Since GTN024 showed tumoricidal effects in an ROS-dependent
manner, we hypothesized that GTN024 would cause excessive
endoplasmic reticulum (ER) stress. We observed that the phos-
phorylation of eIF2a was increased in GTN024-treated MM cells
(Fig. 3A). We also observed an increased amount of cleaved
caspase-3 following treatment with GTN024 (Fig. 3B).3.4. Safety and the anti-MM effects of GTN024 in vivo
To determine the optimal dosage of GTN024 in the KMS11-
xenografted mice model, we administered 10, 20, or 40mg/kg day
of GTN024 to ICR mice by intraperitoneal injection for three
consecutive days (days 1e3). When mice were treated with 40mg/
kg day of GTN024, signiﬁcant weight loss and bowel obstructions
were observed. However, when 10mg/kg day or 20mg/kg day were
given to mice, no loss of body weight was observed (Fig. 4A). No
hematological toxicities were detected at any dosage levels (Fig. 4A).
Given these results, we considered 20mg/kg for three consecutive
days as the maximal tolerated dose for mouse experiments.
To examine the growth-inhibitory effects of GTN024 in vivo, we
intraperitoneally injected 20mg/kg of GTN024 in KMS11-
xenografted mice for three consecutive days. As shown in Fig. 4B,GTN024 signiﬁcantly delayed tumor growth in xenograftedmice. At
14 days after the ﬁrst injection, the average tumor volume was
383mm3 in the GTN024-treated mice, and 843mm3 in the control
mice (p< 0.05).
The H&E staining showed an agglutination of chromatin in the
tumors of GTN024-treated mice (Fig. 4C). Cleaved-caspase-3-
positive and PARP-positive cells were also signiﬁcantly increased
in the GTN024-treated tumors. In contrast, staining with MIB-1, a
strong marker of cell proliferation, was weaker in the tumors of the
GTN024-treated mice compared to those of the control mice
(Fig. 4C).4. Discussion
A number of novel drugs have been derived from natural
products. For example, irinotecan, a derivative of camptothecin that
was originally isolated from the deciduous tree Camptotheca acu-
minata, is now widely used as an anti-cancer agent for lung cancer
and colorectal cancer [24]. Paclitaxel, which is derived from the tree
Taxus brevifolia, induces the apoptosis of cancer cells via binding to
b-tubulin, inducing depolymerization and stabilizing microtubules
[25]. A variety of molecular-targeting agents have been developed,
but their success is limited to a few malignant diseases such as
chronic myelogenous leukemia.
Multiple myeloma is a genetically heterogenenous disease, and
target molecules (such as a driver gene mutation) have not been
discovered. More therapeutic options including novel compounds
are needed for treating high-risk MM patients to improve their
prognoses and quality of life. The exploitation of clinically effective
drugs is time-consuming and involves signiﬁcant costs. Therefore,
natural products remain an important resource for drug develop-
ment. In this study, we focused on a novel natural compound, KQN,
and its derivative, GTN024 analogues.
Fig. 3. GTN024 induced ER stress-mediated cell death in MUM24 cells. MUM24 cells were treated with GTN024 for 3, 6, 12, or 24 h. The cells were lysed and analyzed by
immunoblotting against eIF2a, p-eIF2a, b-actin, and cleaved caspase-3. The lower band of eIF2a was considered as the degradation of eIF2a [36].
Fig. 4. Toxicity and anti-MM effects of GTN024 in the in vivo model. (A) ICR mice were treated with 10, 20, or 40 mg/kg of GTN024 for three consecutive days (days 1e3). Blood
samples were collected from tail veins. Leukocyte and neutrophil numbers were counted after Türk's solution staining. Bars: mean ± SD, n ¼ 3. *p < 0.05 vs. control. (B) Suppressed
growth of MM cells in the xenograft mouse model by GTN024 20 mg/kg. GTN024 was given when xenografted tumor exceeded 100 mm3. GTN024 20 mg/kg was given intra-
peritoneally on days 1e3. Bars: mean ± SD. *p < 0.05 (control vs. GTN024). (C) Stained xenografted tumor of a GTN024-treated mouse. Xenograft tumors in mice after treatment
with or without GTN024 were collected and stained with H&E, anti-cleaved caspase-3, anti-cleaved PARP, anti-MIB-1, and anti-PCNA.
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above-cited structure-activity relationship study revealed that the
hydroquinone moiety is necessary to potent anti-tumor effects of
these compounds [20]. Among them, GTN024, which has a ben-
zoquinone moiety, showed signiﬁcant anti-MM effects, and was
readily accessible because it has only a single chiral carbon [20]. We
therefore conducted further research regarding GTN024.
Our present ﬁndings demonstrated that GTN024 had in vitro
anti-MM effects against MM cell lines and clinical samples obtained
from MM patients including those with high-risk chromosomal
abnormalities, indicating that GTN024 is a promising candidate fortreating MM patients with high-risk cytogenic changes.
As described in results, we concluded that 20mg/kg for 3 days is
the maximum tolerated dose for our mouse model. In our mouse
xenograft model, signiﬁcant anti-MM effects were produced by the
same schedule of drug administration without severe toxicities.
The results of the histopathological examination conﬁrmed that
GTN024 caused the apoptosis of xenografted tumors.
KQN, the mother compound of GTN024, was reduced by TcOYE
to its semiquinone form, and the production of ROS is the key
mechanism of anti-trypanocidal effects [18,19]. In the present
study, we observed that GTN024 showed ROS production and
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oxidants. We therefore speculate that the anti-MM effects of
GTN024 are due mainly to the cytotoxicity by ROS. Several ROS-
mediated compounds have also shown signiﬁcant cytotoxicity
against MM cells, via various pathways such as the inhibition of
thioredoxin 1 by PX-12 [26], DNA damage by an ATR inhibitor [27],
and the activation of p53 by CP-31398 [28]. It is thus apparent that
ROS-mediated cytotoxicity plays an important role in treatments
for MM.
MM cells are characterized by the excessive accumulation of
unfolded M-protein. In this study, we focused on endoplasmic re-
ticulum (ER) stress, because ROS cause the apoptosis of cells by an
excessive ER response, which could be a therapeutic target in MM
[29e32]. ROS induced ER stress via many signals including PERK
andmitochondria pathway [33,34]. Herewe focused on eIF2a, a key
molecule of ER stress, and our ﬁndings showed an increased
phosphorylation of eIF2a in MM cells by GTN024.We also observed
increased level of cleaved caspase-3. These results suggested that
ROS-mediated ER stress is a putative target pathway of GTN024-
induced apoptosis.
In conclusion, we developed GTN024 from a natural product,
KQN, and our present results demonstrated the induction of the
apoptosis of MM cells with high-risk cytogenic abnormalities
in vitro and in vivo. The major merits of using GTN024 in MM
treatments are as follows. First, GTN024 showed cytotoxicity toMM
cells with high-risk chromosomal changes that are resistant to
currently available drugs. Some of the cell lines used in this study
are resistant to lenalidomide or dexamethasone [22,23]. MUM24
cells were established from a thalidomide-resistant patient [22].
Second, in our mouse xenograft model, GTN024 signiﬁcantly
inhibited tumor growth without eminent hematological or sys-
temic side effects when themice were treatedwith 10e20mg/kg of
GTN024. Third, GTN024 induced apoptosis via ROS-mediated
excessive ER stress, to which MM cells were highly vulnerable.
We therefore propose that GTN024 is a promising candidate com-
pound for the treatment of high-risk MM.
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